Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05659381
Other study ID # GOG-3068
Secondary ID 217908
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 8, 2024
Est. completion date August 1, 2038

Study information

Verified date June 2024
Source GOG Foundation
Contact Jennifer Klein, MEd
Phone 6784310300
Email jklein@gog.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1 every 21 days for 3-4 cycles). Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at the time of iCRS (iCRS must achieve no gross residual disease or no disease >1.0 cm in largest diameter) to receive HIPEC or no HIPEC. Patients randomized to HIPEC (Arm A) will receive a single dose of cisplatin (100mg/m2 IP over 90 minutes at 42 C) as HIPEC. After postoperative recovery patients will receive standard post-operative platinum-based combination chemotherapy. Patients randomized to surgery only (Arm B) will receive postoperative standard chemotherapy after recovery from surgery. Both groups will receive an additional 2-3 cycles of platinum-based combination chemotherapy per institutional standard (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1 every 21 days for 2-3 cycles) for a maximum total of 6 cycles of chemotherapy (neoadjuvant plus post-operative cycles) followed by niraparib individualized dosing until progression or 36 months (if no evidence of disease).


Recruitment information / eligibility

Status Recruiting
Enrollment 230
Est. completion date August 1, 2038
Est. primary completion date August 1, 2033
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients must have a pathologic diagnosis of high grade serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, stage III or IV documented on CT scan/MRI, must be recommended to undergo neoadjuvant chemotherapy (3-4 cycles allowed) and are considered candidates for interval cytoreductive surgery (iCRS) as determined by the enrolling investigator. 2. Patients with stage IV disease must have complete response of extra-abdominal disease on preoperative imaging (e.g. pleural effusion, mediastinal, inguinal, supraclavicular lymphadenopathy, or other extra-abdominal metastases). 3. Patient must have no gross residual disease or no disease >1.0 cm in largest diameter following iCRS and prior to randomization. 4. Patients must have Myriad myChoice HRD test results available prior to registration. 5. Patient must have adequate bone marrow and organ function: Bone marrow function: Hemoglobin = 8.5 g/dL. Absolute neutrophil count (ANC) = 1,000/mm3. Platelets = 100,000/mm3. Renal function: Creatinine = 1.3mg/dl Calculated creatinine clearance (= 30 mL/min/1.73 m2) per National Kidney Foundation guidelines and NHANES III Hepatic function: Bilirubin = 1.5 times ULN. ALT = 3 times the ULN. AST = 3 times the ULN. Neurologic function: Peripheral neuropathy = CTC AE grade 2. Blood coagulation parameters: PT with an INR of = 1.5 and a PTT = 1.5 times the ULN. For patients on full-dose oral anti-coagulation (such as warfarin or rivaroxaban), in-range INR (usually between 2 and 3) and a PTT <1.2 times the ULN. 6. Patients must have a GOG performance status of 0 or 1. 7. Patient must be age > 18. 8. Patients must have a life expectancy > 3 months. 9. Patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to iCRS and must be practicing an effective form of contraception (with failure rate <1% per year) during the study period and for 6 months following the last dose of niraparib. Patients of childbearing potential must consent to pregnancy testing prior to receiving niraparib and monthly thereafter for the duration of the study. Patients are considered postmenopausal and not of child-bearing potential if they are free from menses for >1 year or are surgically sterilized. 10. Patients must have normal blood pressure (BP) or adequately treated and controlled hypertension based on local standard of care (systolic BP < 140 mmHg and diastolic < 90 mmHg) 11. Patients receiving corticosteroids may continue as long as their dose is stable for at least 4 weeks prior to randomization. 12. Patients must agree to not donate blood during the study or for 90 days after the last dose of study treatment. 13. Patients with known human immunodeficiency virus (HIV) are allowed if they meet all of the following criteria: 1. Cluster of differentiation 4 =350/µL and viral load <400 copies/mL 2. No history of acquired immunodeficiency syndrome-defining opportunistic infections within 12 months prior to randomization 3. No history of HIV associated malignancy for the past 5 years 4. Concurrent antiretroviral therapy as per the most current National Institutes of Health (NIH) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV started >4 weeks prior to randomization. Exclusion Criteria 1. Patients with low-grade serous, clear cell, mucinous, non-epithelial ovarian cancers and borderline tumors. 2. Patients who have received prior treatment for ovarian cancer other than the first 3-4 cycles of platinum based neoadjuvant chemotherapy. 3. Patients not eligible for iCRS based on evidence of progression of disease during neoadjuvant chemotherapy (documented on CT scan/MRI required within 28 days of iCRS). 4. Patients not eligible to iCRS based on medical co-morbidites as per enrolling investigator. 5. Patients with stage IV disease without complete response of extra-abdominal disease on preoperative imaging (e.g., pleural effusion, mediastinal, inguinal, supraclavicular lymphadenopathy, or other extra-abdominal metastases) who are not deemed resectable with iCRS. 6. Patients with a history of Myelodysplastic Syndrome or Acute Myeloid Leukemia. 7. Patients who are pregnant or lactating. 8. Patients with a hypersensitivity or allergy to paclitaxel, docetaxel, carboplatin, cisplatin, or niraparib. 9. Patients with a severe infection requiring IV antibiotics within 2 weeks of planned randomization. 10. Patients with other uncontrolled, inter-current medical conditions. 11. Patient with metastatic disease to the central nervous system. 12. Patient with uncontrolled insulin dependent diabetes (HbA1c greater than or equal to 6%) or pre-existing renal condition. 13. Patients with pre-existing hearing loss. 14. Patients with Prior Reversible Encephalopathy Syndrome (PRES). 15. Patients with current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease per investigator assessment). Severe hepatic impairment patients should be excluded. 16. Patients with any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels. 17. Patients with clinically significant cardiovascular disease (e.g., significant cardiac conduction abnormalities, uncontrolled hypertension, myocardial infarction, uncontrolled cardiac arrhythmia or unstable angina <6 months prior to randomization, New York Heart Association Grade 2 or greater congestive heart failure, serious cardiac arrhythmia requiring medication, Grade 2 or greater peripheral vascular disease, and history of cerebrovascular accident within 6 months). 18. Patients with an increased bleeding risk due to concurrent conditions (e.g., major injuries or major surgery within the past 28 days prior to study randomization and/or history of hemorrhagic stroke, transient ischemic attack, subarachnoid hemorrhage, or clinically significant hemorrhage within the past 3 months). 19. Patients with known active hepatitis B (e.g., hepatitis B surface antigen reactive) are excluded unless their HBV is stably controlled on nucleos(t)ide analogs (e.g. entecavir or tenofovir) which will be continued for the duration of the study. A patient who is HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution should be eligible. 20. Patient has had investigational therapy administered within 4 weeks or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to study randomization. 21. Patient has received a live vaccine within 30 days of study randomization. COVID19 vaccines that do not contain live viruses are allowed at any time during study treatment. 22. Patient has a diagnosis, detection, or treatment of another type of cancer = 2 years prior to randomization (except basal or squamous cell carcinoma of the skin and cervical cancer in situ that has been definitively treated) 23. Patients who have had radiotherapy encompassing > 20% of the bone marrow within 2 weeks of randomization; or any radiation therapy within 1 week prior to randomization.

Study Design


Intervention

Drug:
Cisplatin
Cisplatin 100mg/m2 IP over 90 minutes at 42 degrees Celcius
Other:
No treatment
No treatment with Cisplatin

Locations

Country Name City State
United States UH Geauga Medical Center Chardon Ohio
United States TriHealth Cancer Institute - Good Samaritan Hospital Cincinnati Ohio
United States TriHealth Cancer Institute- Thomas Comprehensive Care Center Cincinnati Ohio
United States University Hospitals Cleveland Medical Center Cleveland Ohio
United States Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center Coral Gables Florida
United States University of Miami Hospital and Clinics - Deerfield Beach Deerfield Beach Florida
United States Baylor College of Medicine Medical Center Houston Texas
United States O'Quinn Medical Tower at McNair Campus Houston Texas
United States Jefferson Hospital Jefferson Hills Pennsylvania
United States University of Kentucky Medical Center Lexington Kentucky
United States SCC at Lake University Mentor Ohio
United States University of Miami Hospital and Clinics Miami Florida
United States Forbes Hospital Monroeville Pennsylvania
United States Smilow Cancer Hospital at Yale- New Haven New Haven Connecticut
United States Yale University School of Medicine New Haven Connecticut
United States Hoag Memorial Hospital Presbyterian Newport Beach California
United States UH Minoff Health Center at Chagrin Highlands Orange Village Ohio
United States West Penn Hospital Pittsburgh Pennsylvania
United States Sylvester Comprehensive Cancer Center - Plantation Plantation Florida
United States Holy Name Medical Center Teaneck New Jersey
United States St. John Medical Center Westlake Ohio
United States Wexford Hospital Wexford Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
GOG Foundation GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival From enrollment until time of disease progression or death, whichever occurs first, or date of last contact if neither progression of death has occured, assessed up to 8 years
Secondary Overall Survival From enrollment to the time of death or date of last contact, assessed up to 8 years
Secondary Frequency and severity of adverse events Every 28 days up to 3 years
Secondary Effect of homologous recombination repair deficiency To assess the effect of homologous recombination repair deficiency (HRD) as defined by standard of care Myriad myChoice HRD test on Progression-free survival and Overall Survival From the time of randomization until the date of first documented disease progression or death from any cause, whichever came first, assessed up to 8 years
Secondary Stage of diagnosis at Progression-Free Survival timepont From the time of randomization until the date of first documented disease progression or death from any cause, whichever came first, assessed up to 8 years
Secondary Stage of diagnosis at Overall Survival timepoint From the time of randomization until the date of first documented disease progression or death from any cause, whichever came first, assessed up to 8 years
Secondary Residual Disease At time of surgery
See also
  Status Clinical Trial Phase
Completed NCT01010126 - Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Phase 2
Terminated NCT00899093 - YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
Completed NCT00301756 - Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors Phase 2
Completed NCT00262847 - Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Phase 3
Recruiting NCT01000259 - Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer N/A
Completed NCT00066456 - Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer Phase 1
Withdrawn NCT00551265 - Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy N/A
Completed NCT03188432 - Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase 2
Completed NCT03297489 - Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer Early Phase 1
Withdrawn NCT00053235 - Research Study in Patients With Advanced Ovarian Epithelial Cancer N/A
Completed NCT00194714 - Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab Phase 1/Phase 2
Terminated NCT02441140 - Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis N/A
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Terminated NCT00003532 - Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer Phase 2
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Completed NCT01551745 - Salvage Ovarian FANG™ Vaccine + Bevacizumab Phase 2
Not yet recruiting NCT06315270 - To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer
Withdrawn NCT02872519 - PET Imaging of Ovarian Carcinoma With 18F-FSPG Early Phase 1
Withdrawn NCT02567396 - Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Phase 1
Withdrawn NCT02470559 - Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent Phase 1